Our study offers novel perspectives into DDX17's oncogenic role in HCC progression, and the applicability of CXCR1/2 inhibitors to block DDX17-mediated CXCL8 signaling activation might be a potential strategy for HCC treatment. Here, DDX17 is linked to hepatocellular carcinoma.